首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1858825

生物偶聯市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

Bioconjugation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年10月15日 | 出版商:

Global Market Insights Inc. | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球生物偶聯市場價值為 56 億美元，預計到 2034 年將以 14.4% 的複合年成長率成長至 206 億美元。

這一上升趨勢與慢性病盛行率的上升以及對生物製劑和新一代療法的需求不斷成長密切相關。隨著醫療保健系統和製藥業將重心轉向個人化治療和精準醫療，對生物偶聯工具和服務的需求持續成長。生物偶聯透過將生物分子與藥物或合成材料進行化學連接，在標靶治療、診斷和研究創新方面發揮至關重要的作用。這些連接後的分子具有更高的性能、更精準的治療效果和更大的治療潛力。不斷擴充的先進療法研發管線和生物技術研究投入的增加，正顯著推動市場對該技術的接受度。企業正擴大將這些技術整合到藥物開發流程中，進一步推進其在疾病檢測、治療和生物標記追蹤方面的應用。市場領導者的強大影響力、先進生物偶聯試劑盒的普及以及對開發穩定且特異性生物分子連接的重視，共同促進了該領域的強勁成長。隨著創新加速，該行業湧現出更多精簡和高效的解決方案，從而促進了其在生物技術、製藥和診斷領域的更廣泛應用。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	56億美元
預測值	206億美元
複合年成長率	14.4%

預計2025年至2034年間，服務領域的複合年成長率將達到15.3%。這一成長主要得益於製藥和生物技術公司外包業務的激增，這些公司正轉向合約研究和生產組織（CRMO）來管理複雜的生物偶聯任務。這些合作關係有助於企業最大限度地降低營運成本，加快研發週期，並更快地將抗體藥物偶聯物和精準療法等標靶治療推向市場。因此，全球藥物研發管線對生物偶聯服務的需求日益成長。

2024年，抗體市場規模達23億美元。抗體因其卓越的靶向能力，在生物偶聯技術中發揮至關重要的作用。它們在藥物偶聯物中的廣泛應用源於其識別並結合特定疾病標記的能力，從而實現更精準的治療藥物遞送，同時減少對健康組織的損傷。除了治療應用外，抗體在診斷和成像平台中也扮演著不可或缺的角色，因為在這些平台中，精準的生物標記檢測至關重要。

預計到2024年，美國生物偶聯市場規模將達22億美元。美國強大的生物技術企業基礎、充足的科學研究經費以及有利的監管環境，為其在該領域的領先地位提供了有力支撐。此外，美國還擁有大量創新生物偶聯療法在研產品線和正在進行的臨床試驗。尖端技術的普及和世界級研究機構的存在，不斷拓展生物偶聯技術的應用邊界。

推動全球生物偶聯市場成長與創新的關鍵企業包括：賽多利斯（Sartorius）、藥明生物（WuXi Biologics）、安捷倫科技（Agilent Technologies）、查爾斯河實驗室（Charles River Laboratories）、賽默飛世爾科技（Thermo Fisher Scientific）、西根（SeagenativeVkgenative Biolabs、BD、金斯瑞生物科技（GenScript Biotech Corporation）、丹納赫公司（Danaher Corporation）、伯樂生物（Bio-Rad Laboratories）、Abzena、龍沙集團（Lonza Group）、Piramal Pharma Limited、基因泰克（羅氏集團）（Genentech (Roche Group)）和Catalent。為了保持競爭優勢，生物偶聯市場的企業正致力於透過積極的研發投入和持續的技術創新來增強其產品線。一些公司正透過與製藥和生物技術公司建立策略聯盟來擴展其服務能力，從而提供客製化解決方案。許多企業也在擴大生產規模並加強全球供應鏈，以滿足對可偶聯生物分子和試劑盒日益成長的需求。主要企業正透過引入先進的偶聯化學技術來提高藥物的穩定性和精確度，從而強調產品組合的多元化。

產業生態系分析
產業影響因素
- 成長促進因素
  - 慢性病盛行率上升
  - 標靶治療的進展
  - 生物偶聯物的法規核准
  - 診斷領域應用範圍的擴大
- 產業陷阱與挑戰
  - 生物偶聯過程的複雜性
  - 高昂的生產和開發成本
- 市場機遇
  - 開發個人化和精準基因療法
  - 隨著醫療基礎設施的不斷發展，新興市場將迎來擴張。
成長潛力分析
監管環境
- 北美洲
  - 美國
  - 加拿大
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲
技術格局
- 當前趨勢
- 新興技術
未來市場趨勢
波特的分析
PESTEL 分析

第4章：競爭格局

介紹
公司市佔率分析
- 全球的
- 北美洲
- 歐洲
- 亞太地區
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
關鍵進展
- 併購
- 夥伴關係與合作
- 新產品發布
- 擴張計劃

第5章：市場估算與預測：依組件分類，2021-2034年

主要趨勢
產品
- 按類型
  - 消耗品
    - 試劑和試劑盒
    - 標籤
    - 其他消耗品
  - 儀器
    - 色譜系統
    - 光譜儀
    - 質譜儀
    - 流式細胞儀
    - 電泳設備
    - 過濾系統
    - 攪拌器和搖酒器
    - 孵化器
    - 其他樂器
- 按最終用途
  - 製藥和生物技術公司
  - 合約研究組織 (CRO) 和合約生產組織 (CMO)
  - 醫院、診所、診斷實驗室
  - 學術和研究機構
服務
- 按類型
  - 客製化合成和偶聯服務
  - 分析和表徵服務
  - 規模化和製造服務
  - 其他服務
- 按最終用途
  - 製藥和生物技術公司
  - 醫院、診所、診斷實驗室
  - 學術和研究機構

第6章：市場估算與預測：依生物分子類型分類，2021-2034年

主要趨勢
抗體
蛋白質
胜肽
寡核苷酸
其他生物分子

第7章：市場估計與預測：依技術分類，2021-2034年

主要趨勢
化學偶聯
酶介導的結合
點擊化學
光反應交聯
其他技術

第8章：市場估算與預測：依應用領域分類，2021-2034年

主要趨勢
療法
- 抗體-藥物偶聯物
- 蛋白質-藥物偶聯物
- 胜肽-藥物偶聯物
- 其他治療應用
研究與開發
診斷
其他應用

第9章：市場估計與預測：依地區分類，2021-2034年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第10章：公司簡介

Abzena
AbbVie
Agilent Technologies
BD
Bio-Rad Laboratories
Catalent
Charles River Laboratories
Creative Biolabs
Danaher Corporation
GenScript Biotech Corporation
Genentech (Roche Group)
Lonza Group
Merck KGaA
Piramal Pharma Limited
Sartorius
Seagen
Thermo Fisher Scientific
WuXi Biologics

簡介目錄

Product Code: 14912

The Global Bioconjugation Market was valued at USD 5.6 billion in 2024 and is estimated to grow at a CAGR of 14.4% to reach USD 20.6 billion by 2034.

The upward trend is closely linked to the rising prevalence of chronic illnesses and the increasing demand for biologics and next-generation therapies. As healthcare systems and pharmaceutical industries shift focus toward personalized treatments and precision medicine, the need for bioconjugation tools and services continues to expand. Bioconjugation plays a critical role in enabling the development of targeted therapeutics, diagnostics, and research innovations by chemically linking biomolecules to drugs or synthetic materials. These linked molecules offer enhanced performance, precision, and therapeutic potential. The expanding pipeline of advanced therapeutics and the growing investment in biotechnology research are significantly boosting market adoption. Companies are increasingly integrating these technologies into drug development workflows, further advancing applications in disease detection, treatment, and biomarker tracking. The strong presence of market leaders, availability of advanced bioconjugation kits, and emphasis on developing stable and specific biomolecule linkages all contribute to the robust growth of this sector. As innovation accelerates, the industry is seeing more streamlined and efficient solutions, facilitating broader use across biotech, pharma, and diagnostics.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$5.6 Billion
Forecast Value	$20.6 Billion
CAGR	14.4%

The services segment is expected to grow at a CAGR of 15.3% during 2025-2034. This growth is being fueled by a surge in outsourcing from pharmaceutical and biotech firms, which are turning to contract research and manufacturing organizations to manage complex bioconjugation tasks. These partnerships help companies minimize operational expenses, speed up development cycles, and bring targeted treatments like antibody-drug conjugates and precision therapies to market faster. As a result, bioconjugation services are seeing increased demand across global drug development pipelines.

In 2024, the antibodies segment generated USD 2.3 billion. Antibodies play a vital role in bioconjugate technologies due to their exceptional targeting capabilities. Their widespread use in drug conjugates stems from their ability to identify and bind to specific disease markers, allowing for more focused delivery of therapeutic agents while reducing harm to healthy tissue. Beyond therapeutics, antibodies are also integral to diagnostic and imaging platforms where accurate biomarker detection is essential.

U.S. Bioconjugation Market reached USD 2.2 billion in 2024. This leadership position is supported by the country's strong base of biotech firms, well-funded research environment, and favorable regulatory framework. The U.S. also benefits from a pipeline filled with innovative bioconjugated therapies and a wealth of ongoing clinical trials. Access to cutting-edge technologies and the presence of world-renowned research institutions continue to push the boundaries of what bioconjugation can achieve.

Key companies driving growth and innovation in the Global Bioconjugation Market include Sartorius, WuXi Biologics, Agilent Technologies, Charles River Laboratories, Thermo Fisher Scientific, Seagen, Merck KGaA, AbbVie, Creative Biolabs, BD, GenScript Biotech Corporation, Danaher Corporation, Bio-Rad Laboratories, Abzena, Lonza Group, Piramal Pharma Limited, Genentech (Roche Group), and Catalent. To maintain a competitive edge, companies in the Bioconjugation Market are focusing on enhancing their product pipelines through aggressive R&D investment and continuous technology innovation. Several firms are expanding their service capabilities by entering strategic alliances with pharmaceutical and biotechnology companies to offer custom solutions. Many players are also scaling up manufacturing facilities and strengthening global supply chains to support increasing demand for conjugation-ready biomolecules and kits. Key businesses are emphasizing portfolio diversification by introducing advanced conjugation chemistries that improve drug stability and precision.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/Country
1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
1.5 Primary research and validation
- 1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis
2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Component trends
- 2.2.3 Biomolecule type trends
- 2.2.4 Technique trends
- 2.2.5 Application trends
2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of chronic diseases
  - 3.2.1.2 Advancements in targeted therapies
  - 3.2.1.3 Regulatory approvals for bioconjugates
  - 3.2.1.4 Expanding applications in diagnostics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Complexity of bioconjugation processes
  - 3.2.2.2 High production and development costs
- 3.2.3 Market opportunities
  - 3.2.3.1 Development of personalized and precision gene therapies
  - 3.2.3.2 Expansion in emerging markets with growing healthcare infrastructure
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 North America
  - 3.4.1.1 U.S.
  - 3.4.1.2 Canada
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.4.4 Latin America
- 3.4.5 Middle East and Africa
3.5 Technology landscape
- 3.5.1 Current trends
- 3.5.2 Emerging technologies
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
- 4.2.4 Asia Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Product
- 5.2.1 By type
  - 5.2.1.1 Consumables
    - 5.2.1.1.1 Reagents and kits
    - 5.2.1.1.2 Labels
    - 5.2.1.1.3 Other consumables
  - 5.2.1.2 Instruments
    - 5.2.1.2.1 Chromatography systems
    - 5.2.1.2.2 Spectroscopy instruments
    - 5.2.1.2.3 Mass spectrometers
    - 5.2.1.2.4 Flow cytometers
    - 5.2.1.2.5 Electrophoresis equipment
    - 5.2.1.2.6 Filtration systems
    - 5.2.1.2.7 Mixers and shakers
    - 5.2.1.2.8 Incubators
    - 5.2.1.2.9 Other instruments
- 5.2.2 By end use
  - 5.2.2.1 Pharmaceutical and biotechnology companies
  - 5.2.2.2 CROs and CMOs
  - 5.2.2.3 Hospitals, clinics, diagnostic laboratories
  - 5.2.2.4 Academic and research institutes
5.3 Services
- 5.3.1 By type
  - 5.3.1.1 Custom synthesis and conjugation services
  - 5.3.1.2 Analytical and characterization services
  - 5.3.1.3 Scale-up and manufacturing services
  - 5.3.1.4 Other services
- 5.3.2 By end use
  - 5.3.2.1 Pharmaceutical and biotechnology companies
  - 5.3.2.2 Hospitals, clinics, diagnostic laboratories
  - 5.3.2.3 Academic and research institutes

Chapter 6 Market Estimates and Forecast, By Biomolecule Type, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Antibodies
6.3 Proteins
6.4 Peptides
6.5 Oligonucleotides
6.6 Other biomolecules

Chapter 7 Market Estimates and Forecast, By Technique, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Chemical conjugation
7.3 Enzyme-mediated conjugation
7.4 Click chemistry
7.5 Photoreactive crosslinking
7.6 Other techniques

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 Therapeutics
- 8.2.1 Antibody-drug conjugates
- 8.2.2 Protein-drug conjugates
- 8.2.3 Peptide-drug conjugates
- 8.2.4 Other therapeutic applications
8.3 Research and development
8.4 Diagnostics
8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE